Magnetic Resonance-Guided Focused Ultrasound : Current Status and Future Perspectives in Thermal Ablation and Blood-Brain Barrier Opening
- Author:
Eun Jung LEE
1
;
Anton FOMENKO
;
Andres M LOZANO
Author Information
- Publication Type:Review
- Keywords: Alzheimer disease; Blood-brain barrier; Essential tremor; High-intensity focused ultrasound ablation
- MeSH: Alzheimer Disease; Blood-Brain Barrier; Brain; Brain Neoplasms; Essential Tremor; High-Intensity Focused Ultrasound Ablation; Immune System; Magnetic Resonance Imaging; Microbubbles; Models, Animal; Neurodegenerative Diseases; Neurogenesis; Parkinson Disease; Plaque, Amyloid; Sonication; Therapeutic Uses; Transducers; Ultrasonography; United States Food and Drug Administration
- From:Journal of Korean Neurosurgical Society 2019;62(1):10-26
- CountryRepublic of Korea
- Language:English
- Abstract: Magnetic resonance-guided focused ultrasound (MRgFUS) is an emerging new technology with considerable potential to treat various neurological diseases. With refinement of ultrasound transducer technology and integration with magnetic resonance imaging guidance, transcranial sonication of precise cerebral targets has become a therapeutic option. Intensity is a key determinant of ultrasound effects. High-intensity focused ultrasound can produce targeted lesions via thermal ablation of tissue. MRgFUS-mediated stereotactic ablation is non-invasive, incision-free, and confers immediate therapeutic effects. Since the US Food and Drug Administration approval of MRgFUS in 2016 for unilateral thalamotomy in medication-refractory essential tremor, studies on novel indications such as Parkinson's disease, psychiatric disease, and brain tumors are underway. MRgFUS is also used in the context of blood-brain barrier (BBB) opening at low intensities, in combination with intravenously-administered microbubbles. Preclinical studies show that MRgFUS-mediated BBB opening safely enhances the delivery of targeted chemotherapeutic agents to the brain and improves tumor control as well as survival. In addition, BBB opening has been shown to activate the innate immune system in animal models of Alzheimer’s disease. Amyloid plaque clearance and promotion of neurogenesis in these studies suggest that MRgFUS-mediated BBB opening may be a new paradigm for neurodegenerative disease treatment in the future. Here, we review the current status of preclinical and clinical trials of MRgFUS-mediated thermal ablation and BBB opening, described their mechanisms of action, and discuss future prospects.
